ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • cathepsin k inhibitor and osteoarthritis
  • caucasian
  • CB-CAP
  • CB-CAPs
  • CBCL and Psychopathology
  • CCN3
  • CCP
  • CD T cells
  • CD T cells and major histocompatibility complex (MHC)
  • CD T cells and rheumatoid arthritis
  • CD123
  • CD25 and sialadenitis
  • CD27
  • CD28
  • CD4 cells and IL-9
  • CD4+ T cell
  • CD4+ T cells
  • CD4+ T cells and Gene Expression
  • CD4+CTL
  • CD4+T subsets
  • CD56
  • CD70
  • CD8 cells
  • CD8 cells and giant cell arteritis
  • CD8+ T cell
  • CDAi
  • CDAI and SF-36
  • celecoxib
  • cell adhension
  • cell biology
  • Cell biology and citrullination
  • Cell biology and gout
  • Cell biology and macrophage activation syndrome
  • cell biology and methotrexate (MTX)
  • cell biology and neutrophils
  • Cell biology and osteoarthritis
  • cell biology and regulatory cells
  • Cell Death
  • Cell Migration
  • Cell Migration and cytokines
  • Cell Migration and fibroblasts
  • Cell Migration and psoriatic arthritis
  • cell modulation
  • cell modulation and systemic lupus erythematosus (SLE)
  • Cell Signaling
  • Cell Signaling and systemic lupus erythematosus (SLE)
  • Cell Signaling and therapeutic targeting
  • cell subsets and Gene Expression
  • Cell therapy
  • cell therapy and adenosine
  • Cell Trafficking Angiogenesis
  • cell-cell fusion and RNAseq
  • Cell-signalling molecules
  • cellular interaction
  • cellular response and autoantibody production
  • cenerimod
  • central nervous system involvement
  • central nervous system involvement and osteoarthritis
  • central nervous system involvement and psychological status
  • central nervous system involvement and systemic lupus erythematosus (SLE)
  • Central nervous system involvement and vasculitis
  • Central retinal vascular occlusive events
  • central sensitization
  • Central sentivity syndrome
  • Central sentivity syndrome and pain management
  • CER
  • ceramides
  • Cerebritis
  • Cerebrovascular disease
  • Cerebrovascular disease and giant cell arteritis
  • cerebrovascular disease and meta-analysis
  • cerebrovascular disease and rheumatoid arthritis (RA)
  • Cerebrovascular disease and risk assessment
  • cerebrovascular disease and systemic lupus erythematosus (SLE)
  • cerebrovascular disease and systemic sclerosis
  • cerebrovascular disease and vasculitis
  • certolizumab pegol
  • certolizumab pegol and clinical research
  • certolizumab pegol and extraarticular manifestations
  • certolizumab pegol and joint damage
  • certolizumab pegol and non-radiographic
  • Certolizumab pegol and pregnancy
  • certolizumab pegol and psoriatic arthritis
  • certolizumab pegol and remission
  • certolizumab pegol and rheumatoid arthritis
  • certolizumab pegol and rheumatoid arthritis (RA)
  • certolizumab pegol and spondylarthritis
  • certolizumab pegol and spondylarthropathy
  • certolizumab pegol and treatment
  • certolizumab pegol and uveitis
  • certolizumab pegol and work
  • Cervical spine
  • cervical spine and fibromyalgia
  • Cervical spine and pain
  • cervical spine and pseudogout
  • Cervical spine involvement
  • chagas
  • checkpoint inhibitors
  • Checkpoint Inhibitors and registry
  • Chemokine Receptors
  • Chemokine Receptors and CD8 cells
  • Chemokine Receptors and T cells
  • chemokines
  • chemokines and biomarkers
  • chemokines and Cell Migration
  • chemokines and cytokines
  • chemokines and inflammation
  • chemokines and interleukins (IL)
  • chemokines and pathogenesis
  • chemokines and plasma cells
  • chemokines and platelets
  • chemokines and psoriatic arthritis
  • chemokines and rheumatoid arthritis (RA)
  • chemokines and salivary gland
  • chemokines and synovium
  • Chemokines and systemic lupus erythematosus (SLE)
  • chemokines and systemic sclerosis
  • chemokines and thrombosis
  • Chemokines and tumor necrosis factor (TNF)
  • Chest CT
  • child
  • Childhood
  • childhood lupus
  • childhood-onset lupus
  • Childhood-onset systemic lupus erythematosus
  • children
  • CHIP
  • Cholesterol
  • cholesterol and atherosclerosis
  • cholesterol and hdl
  • cholesterol and lipids
  • cholesterol and myositis
  • cholesterol and osteoarthritis
  • cholesterol and physical activity
  • cholesterol and psoriatic arthritis
  • cholesterol and rheumatic disease
  • cholesterol and rheumatoid arthritis
  • Cholesterol and rheumatoid arthritis (RA)
  • cholesterol and statins
  • cholesterol and systemic lupus erythematosus (SLE)
  • Cholesterol loading
  • cholesterol loading capacity of serum
  • Choline
  • choline and osteophyte
  • cholinergic agonists
  • cholinergic agonists and osteoclasts
  • Chondrocalcinosis
  • chondrocalcinosis and computed tomography (CT)
  • Chondrocalcinosis and osteoarthritis
  • chondrocalcinosis and pseudogout
  • chondrocalcinosis and radiography
  • chondrocalcinosis and seropositive
  • chondrocalcinosis and ultrasonography
  • chondrocyte
  • chondrocytes
  • chondrocytes and inflammation
  • chondrocytes and mitochondria
  • chondrocytes and osteoarthritis
  • Chondrocytes and osteoarticular
  • chondrocytes and proteomics
  • chondrocytes and stress
  • Chondrocytes and tendonitis/bursitis
  • chondrocytes and toll-like receptors
  • chondrocytes and transcription factor
  • chondrocytes and transforming growth factor
  • Chondrogenesis
  • chondroitin
  • chondroitin and pain management
  • Chronic disease
  • Chronic disease care
  • chronic disease care and rheumatoid arthritis (RA)
  • Chronic fatigue syndrome
  • chronic inflammatory rheumatic diseases
  • Chronic kidney disease
  • chronic low back pain
  • chronic low back pain and cross-sectional studies
  • chronic low back pain and diagnostic imaging
  • Chronic low back pain and psoriatic arthritis
  • chronic low back pain and quality of life
  • Chronic musculoskeletal pain
  • Chronic non-bacterial osteomyelitis
  • Chronic pain
  • Chronic pain and Chronic pain
  • Chronic pain and Health Assessment Questionnaire
  • Chronic pain and low back pain
  • Chronic pain and opioids
  • Chronic pain and population studies
  • Chronic pain and PROMIS
  • Chronic pain and treatment
  • Chronic recurrent multifocal osteomyelitis
  • Chronic recurrent multifocal osteomyelitis (CRMO)
  • chronic recurrent multifocal osteomyelitis (CRMO) and osteomyelitis
  • Chronic recurrent multifocal osteomyelitis (CRMO) and pediatric rheumatology
  • Chronic Rheumatic Diseases
  • Churg-Strauss syndrome
  • Churg-Strauss syndrome and rituximab
  • Churg-Strauss syndrome and thrombosis
  • Churg-Strauss syndrome and treatment
  • Churg-Strauss syndrome and vasculitis
  • CITE-seq
  • First |
  • « Previous Page
  • 7
  • 8
  • 9
  • 10
  • 11
  • [12]
  • 13
  • 14
  • 15
  • 16
  • 17
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology